Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naratriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 13/20 | 0.96 |
| ▸ | HTR1B known ✓ | P28222 | 13/20 | 0.96 |
| ▸ | HTR1A | P08908 | 2/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | HTR1F | P30939 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naratriptan SCHEMBL68753 | 0.98 | HTR1D (1.00) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL29403931 | 0.98 | HTR1D (1.00) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL41527 | 0.97 | HTR1D (0.98) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL30903899 | 0.97 | HTR1D (0.98) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL12803311 | 0.97 | HTR1D (0.98) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL28587084 | 0.97 | HTR1D (0.98) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| SCHEMBL9272206 | 0.92 | HTR1D (0.88) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9274904 | 0.91 | HTR1D (0.86) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| SCHEMBL11946673 | 0.90 | HTR1D (0.84) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| SCHEMBL12936350 | 0.88 | HTR1D (0.81) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| US-11623052-B2 | Dry powder drug delivery system and methods | MANNKIND CORPORATION (US) | 2023-04-11 | — | — | US | claimed |
| WO-2021078412-A1 | FRACTAL FORMULATIONS | MESSADEK JALLAL (BE) | 2021-04-29 | — | — | WO | claimed |
| US-10744280-B2 | Dry powder drug delivery system and methods | MANNKIND CORPORATION (US) | 2020-08-18 | — | — | US | claimed |
| US-20200147076-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2020-05-14 | — | — | US | claimed |
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2019-01-03 | — | — | US | claimed |
| CN-108785289-A | Molten film of naratriptan hydrochloride mouth and preparation method thereof | 北京太阳升高科医药研究股份有限公司 | 2018-11-13 | — | — | CN | claimed |
| US-20180296556-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2018-10-18 | — | — | US | claimed |
| EP-3082813-B1 | USE OF NARATRIPTAN IN THE TREATMENT OF ROSACEA | GALDERMA RES & DEV (FR) | 2018-05-16 | — | — | EP | claimed |
| US-9889126-B2 | Use of naratriptan in the treatment of rosacea | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-02-13 | — | — | US | claimed |
| EP-1294359-A1 | PROCESS FOR PREPARING AND HARVESTING CRYSTALLINE PARTICLES | GLAXO GROUP LIMITED (GB) | 2003-03-26 | — | — | EP | claimed |
| EP-1294360-A1 | NOVEL PROCESS FOR PREPARING AND HARVESTING CRYSTALLINE PARTICLES | GLAXO GROUP LIMITED (GB) | 2003-03-26 | — | — | EP | claimed |
| US-20020099059-A1 | Combination therapy for the treatment of migraine | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-25 | — | — | US | claimed |
| WO-2002017896-A2 | COMBINATION FOR THE TREATMENT OF MIGRAINE COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND ACETYLSALICYLIC ACID | PATTEN PETER VAN (US) | 2002-03-07 | — | — | WO | claimed |
| WO-2002015899-A1 | COMBINATION THERAPY FOR THE TREATMENT OF MIGRAINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
| CN-1335787-A | Apparatus and method for preparing crystalline particles | GLAXO GROUP LTD (GB) | 2002-02-13 | — | — | CN | claimed |
| WO-2002000199-A1 | NOVEL PROCESS FOR PREPARING AND HARVESTING CRYSTALLINE PARTICLES | GLAXO GROUP LIMITED (GB) | 2002-01-03 | — | — | WO | claimed |
| WO-2002000198-A1 | PROCESS FOR PREPARING AND HARVESTING CRYSTALLINE PARTICLES | GLAXO GROUP LIMITED (GB) | 2002-01-03 | — | — | WO | claimed |
| EP-1144065-A1 | APPARATUS AND PROCESS FOR PREPARING CRYSTALLINE PARTICLES | GLAXO GROUP LIMITED (GB) | 2001-10-17 | — | — | EP | claimed |
| WO-2000038811-A1 | APPARATUS AND PROCESS FOR PREPARING CRYSTALLINE PARTICLES | GLAXO GROUP LIMITED (GB) | 2000-07-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | HTR1D 3424/4885HTR1B 2411/4885HTR1A 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.